The moderate hypofractionated radiotherapy course (3-weeks with concomitant boost) resulted in comparable safety and efficacy to the normal fractionation (4-6...

In DESTINY-Lung02 trial Presented by Dr. Koichi Goto, Trastuzumab deruxtecan (T-DXd) 5.4 mg/kg and 6.4 mg/kg demonstrated clinically meaningful activity...

A locally applied, silicone-based polyurethane film dressing (Mepitel Film) can reduce #radiation induced skin toxicities in #breast_cancer patients. According a...

In IPSOS trial Presented by Dr. Siow Ming Lee, 1L #atezolizumab significantly improved OS vs single-agent chemo in platinum-ineligible pts...

The combination of #Enzalutamide (ENZ) Plus #Abiraterone Acetate and Prednisolone (AAP) is NOT Recommended for #mHSPC based on the recent...

#Radiation_therapy boost improved local control in DCIS of the breast with one or more risk factors as recently shown by...

First results of the RADICALS-HD trial presented by Dr. Chris Parker demonstrated that in patients having post-operative radiotherapy after...

In SWOG S1801 study presented by Dr. Sapna Patel, #neoadjuvant treatment (NAT) with #pembrolizumab showed a significant EFS benefit compared...

In phase III CodeBreak 200 trial presented by Dr. Melissa Johnson, oral #sotorasib demonstrated superior PFS and ORR compared to...

In CABASTY trial presented by Dr. Stephane Oudard, #Cabazitaxel 16 mg/m2 every 2 weeks (CBZ q2w) + G-CSF was compared...